Andrew Perlman

Dr. Andrew J.
Perlman is an Independent Director at Arcus Biosciences, Inc., a Chief Medical Officer & Managing Director at Velocity Pharmaceutical Development LLC, an Advisor at Avestria Ventures Management LLC, a CEO, Chief Financial Officer & Secretary at Spitfire Pharma, Inc. and a Managing Director & Head-Non-Clinical Development at X-37 Service Co., Inc. He is on the Board of Directors at Arcus Biosciences, Inc. Dr. Perlman was previously employed as a Venture Partner by Presidio Partners, a Chief Executive Officer & Director by Innate Immune, Inc., an Executive Vice President by Tularik, Inc., a Chief Executive Officer & Director by Affymax, Inc., a Senior Director-Clinical Research by Genentech, Inc., an Executive Vice President by Tularik, Inc., and a President by Vitesse Biologics LLC.
He also served on the board at ISTA Pharmaceuticals, Inc. He received his undergraduate degree from Massachusetts Institute of Technology and a doctorate degree from New York University.